MX2019013776A - Tratamiento de tumores solidos utilizando coenzima q10. - Google Patents

Tratamiento de tumores solidos utilizando coenzima q10.

Info

Publication number
MX2019013776A
MX2019013776A MX2019013776A MX2019013776A MX2019013776A MX 2019013776 A MX2019013776 A MX 2019013776A MX 2019013776 A MX2019013776 A MX 2019013776A MX 2019013776 A MX2019013776 A MX 2019013776A MX 2019013776 A MX2019013776 A MX 2019013776A
Authority
MX
Mexico
Prior art keywords
coenzyme
treatment
solid tumors
subject
coq1o
Prior art date
Application number
MX2019013776A
Other languages
English (en)
Inventor
Patrick Mccook John
Rajin Narain Niven
Y Song Paul
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of MX2019013776A publication Critical patent/MX2019013776A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención aporta los métodos y las composiciones para el tratamiento de un individuo con un tumor sólido, que consisten en administrar coenzima Q10 (CoQ10), en particular cuando el individuo no ha respondido a al menos un régimen quimioterapéutico anterior.
MX2019013776A 2012-06-01 2014-11-27 Tratamiento de tumores solidos utilizando coenzima q10. MX2019013776A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261654245P 2012-06-01 2012-06-01

Publications (1)

Publication Number Publication Date
MX2019013776A true MX2019013776A (es) 2020-01-30

Family

ID=49673946

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014014492A MX369768B (es) 2012-06-01 2013-05-31 Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer.
MX2019013776A MX2019013776A (es) 2012-06-01 2014-11-27 Tratamiento de tumores solidos utilizando coenzima q10.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014014492A MX369768B (es) 2012-06-01 2013-05-31 Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer.

Country Status (17)

Country Link
US (3) US20140017317A1 (es)
EP (1) EP2854528B8 (es)
JP (3) JP6352905B2 (es)
KR (2) KR102163948B1 (es)
CN (1) CN104507308A (es)
AU (2) AU2013267166A1 (es)
BR (1) BR112014029954A2 (es)
CA (2) CA2875150C (es)
EA (1) EA032345B1 (es)
ES (1) ES2761449T3 (es)
HK (1) HK1208995A1 (es)
IL (1) IL236008B (es)
IN (1) IN2014DN10734A (es)
MX (2) MX369768B (es)
NZ (1) NZ702369A (es)
SG (1) SG11201407880QA (es)
WO (1) WO2013181639A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120034649A (ko) 2009-05-11 2012-04-12 버그 바이오시스템즈, 엘엘씨 환경대사적 전환인자（조효소 ｑ１０）를 사용한 질환의 치료 방법
ES2762451T3 (es) 2011-04-04 2020-05-25 Berg Llc Tratamiento de tumores del sistema nervioso central con coenzima Q10
JP6352905B2 (ja) * 2012-06-01 2018-07-04 バーグ エルエルシー コエンザイムｑ１０を用いた固形腫瘍の治療
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
JP6595478B2 (ja) 2013-09-04 2019-10-23 バーグ エルエルシー コエンザイムｑ１０の連続注入によるがんの治療方法
US9996463B2 (en) * 2015-11-10 2018-06-12 International Business Machines Corporation Selection and placement of volumes in a storage system using stripes
WO2017087576A1 (en) * 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20170255565A1 (en) * 2016-03-02 2017-09-07 Intel Corporation Method and apparatus for providing a contiguously addressable memory region by remapping an address space
US20200093751A1 (en) * 2016-06-28 2020-03-26 Der-Yang Tien Chemoprotective/chemoactive nanodroplets and methods of use thereof
AU2018269377A1 (en) * 2017-05-17 2019-12-19 Berg Llc Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa
WO2023099436A1 (en) * 2021-12-01 2023-06-08 Gambro Lundia Ab New dialysis fluid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
WO2005048925A2 (en) * 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
KR101535395B1 (ko) 2004-01-22 2015-07-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
JPWO2008069276A1 (ja) * 2006-12-06 2010-03-25 株式会社カネカ 癌治療剤および発癌抑制剤
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
MX2010005222A (es) * 2007-11-12 2010-09-28 Bipar Sciences Inc Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales.
AU2008333811B2 (en) 2007-12-04 2014-05-01 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
KR20120034649A (ko) * 2009-05-11 2012-04-12 버그 바이오시스템즈, 엘엘씨 환경대사적 전환인자（조효소 ｑ１０）를 사용한 질환의 치료 방법
NZ602057A (en) * 2010-03-12 2015-06-26 Berg Pharma Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
SG10201605008TA (en) 2011-06-17 2016-07-28 Berg Llc Inhalable pharmaceutical compositions
JP6352905B2 (ja) 2012-06-01 2018-07-04 バーグ エルエルシー コエンザイムｑ１０を用いた固形腫瘍の治療

Also Published As

Publication number Publication date
US20170216223A1 (en) 2017-08-03
MX369768B (es) 2019-11-21
EP2854528A1 (en) 2015-04-08
KR20200118233A (ko) 2020-10-14
WO2013181639A8 (en) 2014-12-31
JP2018168164A (ja) 2018-11-01
JP7225167B2 (ja) 2023-02-20
ES2761449T3 (es) 2020-05-19
JP2015518056A (ja) 2015-06-25
MX2014014492A (es) 2015-05-12
AU2017202567A1 (en) 2017-05-11
NZ702369A (en) 2016-12-23
EP2854528A4 (en) 2016-03-09
EA201492187A1 (ru) 2015-05-29
JP2020183440A (ja) 2020-11-12
AU2013267166A1 (en) 2014-12-18
BR112014029954A2 (pt) 2017-06-27
KR102163948B1 (ko) 2020-10-12
EA032345B1 (ru) 2019-05-31
HK1208995A1 (en) 2016-03-24
IL236008B (en) 2018-08-30
CA2875150A1 (en) 2013-12-05
JP6352905B2 (ja) 2018-07-04
IN2014DN10734A (es) 2015-09-04
US20220096399A1 (en) 2022-03-31
IL236008A0 (en) 2015-02-01
SG11201407880QA (en) 2014-12-30
US20140017317A1 (en) 2014-01-16
CA3090268A1 (en) 2013-12-05
EP2854528B8 (en) 2019-10-23
AU2017202567B2 (en) 2019-06-13
KR20150022932A (ko) 2015-03-04
CN104507308A (zh) 2015-04-08
WO2013181639A1 (en) 2013-12-05
CA2875150C (en) 2020-10-27
EP2854528B1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
MX2019013776A (es) Tratamiento de tumores solidos utilizando coenzima q10.
WO2014018563A3 (en) Methods for the treatment of cancer
IL246544B (en) A compound for the treatment of patients with ros1 mutant cancer cells
MX2019014986A (es) Formulaciones de coenzima q10 y metodos de uso.
EP3046622A4 (en) Positron emission tomography guided proton therapy
PT3456717T (pt) Derivado de 4,6-diamino-quinolina-3-carbonitrilo como modulador do cancro da tiróide de osaka (cot) para o tratamento de doenças inflamatórias
MX2013007773A (es) Terapia anticancer con inhibidores duales de aurora quinasa / mek.
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
WO2014109814A3 (en) Metal complexes, methods, and uses thereof
WO2014116833A3 (en) Compositions and methods for detecting neoplasia
EP4276200A3 (en) Fgfr-tacc fusion proteins and methods thereof
AU2012240222A8 (en) Methods of treating central nervous system tumors
EP3415159A4 (en) PRE-TREATMENT MEDICAMENT FOR T-CELL PERFUSION THERAPY FOR TUMOR RESISTANT TO IMMUNE CONTROL POINT INHIBITORS
WO2014039533A3 (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
PL3394063T3 (pl) Makrocykliczne ligandy z grupą (grupami) pikolinianową, ich kompleksy, jak również zastosowania medyczne
MX2017012553A (es) Compuestos espirociclicos.
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EP2982752A4 (en) Glucuronyl transferase, gene encoding same, and use thereof
PH12015501854A1 (en) Factor ix polypeptide formulations
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS
দৈনিক নয়া দিগন্ত নগরবাসীর সেবা নিশ্চিতে ডিসিসিকে দলীয়করন মুক্ত করা দরকার
UA92917U (uk) Спосіб профілактики ферумдефіцитної анемії поросят
КОлегія ÌÀÍÄвÂÅÖÜ